MONTREAL, June 27 /PRNewswire-FirstCall/ - CryoCath(R) Technologies Inc.,the global leader in cryotherapy products to treat cardiac arrhythmias, todayannounced the introduction of Arctic Front(R) in Italy, Belgium and Spain.Arctic Front, the Company's lead product for the treatment of paroxysmalatrial fibrillation (PAF), is a unique cryoablation balloon catheter thatallows physicians to safely and effectively isolate all four pulmonary veinsfor the treatment of PAF.
"The introduction of Arctic Front in Italy, Belgium and Spain provides uswith an exciting opportunity to deliver the benefits of our breakthroughtherapy to a larger patient population and drive one of our key corporategoals of explosive and profitable revenue growth in Europe," said JanKeltjens, President and CEO of CryoCath. "As was the case in Australia andHong Kong, the European medical community has demonstrated great confidence inArctic Front based on its growing body of clinical evidence. By expanding ouralready strong presence in Europe, we are continuing to drive the adoption ofour Arctic Front system worldwide."
Prof. Dr. Claudio Tondo, Chief of the Cardiology Division and Director ofthe Cardiac Arrhythmia and Heart Failure Research Institute at the SanCamillo-Forlanini Hospital in Rome, Italy performed the first procedures withArctic Front in Italy on June 9, 2008. Dr. Tondo will provide leadership forthe program in Italy, the second largest electrophysiology market incontinental Europe.
"Arctic Front represents a step forward in the ablative strategies foratrial fibrillation. The cryoballoon from CryoCath offers a safe and effectiveapproach favoring a substantial reduction of x-ray exposure time and, withoutthe need to carry out a double transseptal puncture," said Dr. Tondo. "Thecryo technology represents an effective alternative to radiofrequency energyfor safety reasons, prompting the extension of the ablative treatment to alarger population of patients suffering from paroxysmal atrial fibrillation.We are looking forward to a strong contribution towards expanding the use ofthe cryo technology in the ablation of atrial fibrillation."
The first Arctic Front procedures in Belgium were performed in May 2008 byProf. Dr. Pedro Brugada, Head of the Heart Rhythm Management Centre, UZBrussel - Vrije Universiteit Brussel and Dr. Gian Battista Chierchia, DirectorAtrial Fibrillation and Pacing Program. Drs. Brugada and Chierchia havetreated four patients in Brussels to date.
"We see great promise in the procedural simplicity of the Arctic FrontSystem. The cryoballoon's innovative shape facilitates anatomical placement inthe atrium at the ostium of the targeted pulmonary vein," said Dr. Brugada."By its very design, the Arctic Front catheter simplifies the ablation ofpulmonary veins and may reduce procedural time in the treatment of atrialfibrillation, in turn offering greater comfort for the patient and operatoralike."
Prof. Dr. Julian Villacastin and his team at Hospital Clinico San Carlosin Madrid, Spain have treated two patients since first using Arctic Front onJune 24, 2008. The patients treated to date have had successful outcomes andno safety concerns have been reported. "We were very pleased with the ease ofuse afforded by the cryoballoon, its simplicity and the success with our firstpatients. We were particularly impressed with the spontaneous termination ofthe patient's atrial fibrillation during the cryoablation and return of sinusrhythm," said, Dr. Villacastin.
About Arctic Front
Arctic Front is a minimally invasive cryo-balloon catheter designedspecifically to treat paroxysmal Atrial Fibrillation. This bi-directional,double balloon catheter enables physicians to rapidly isolate all fourpulmonary veins for the treatment of AFib. More than 2,600 patients have beentreated in more than 45 centres across Europe.